Complex Generics Drought Could Make Teva Stock ‘Relatively Rudderless’
Israeli Firm Aiming For Gx Forteo, Xulane To Cross The Line In 2023
Executive Summary
The market has responded to Teva’s newly released 2023 financial guidance, with lingering questions over its ability to hit its forecasts amid a continued dearth of complex generics and further investments in Teva’s pipeline.
You may also be interested in...
Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder
The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.
Waverley Weighs Its Options With High Costs, Thin Margins
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.